Every cath lab director eventually faces the same planning question: how many stent platforms, balloon types, and catheter variations does a lab actually need to keep on hand without overcommitting capital to inventory that rarely moves? Building a cath lab device portfolio is fundamentally a balancing act between clinical coverage, physician preference, and the practical economics of inventory. This guide outlines a general framework for thinking through cath lab procurement decisions for coronary and vascular intervention supplies.
What Categories of Devices Belong in a Coronary Cath Lab Portfolio?
A typical coronary-focused cath lab portfolio spans several device categories: diagnostic and guide catheters, guidewires, PTCA balloons (both standard and drug-coated), bare-metal or drug-eluting coronary stents, and closure devices, along with supporting consumables such as sheaths and manifolds. Within each category, labs generally need coverage across a range of sizes — stent diameters and lengths, balloon diameters and lengths, and catheter shapes suited to different coronary anatomies. The exact mix depends heavily on the patient population served, the complexity of cases performed (including chronic total occlusions or heavily calcified lesions), and the number of interventional cardiologists on staff and their individual technique preferences.
How Should Inventory Levels Be Planned Across Device Categories?
Inventory planning for interventional cardiology supplies typically starts with historical case volume and size distribution — which stent diameters and balloon lengths are used most often — and builds par levels around that data rather than stocking every available size equally. High-turnover sizes (mid-range vessel diameters, common lesion lengths) generally warrant deeper stock, while less common sizes may be kept at lower par levels or sourced on a faster reorder cycle. Labs also need to account for shelf life and expiration dating on drug-coated and drug-eluting devices, since these products carry finite shelf lives tied to their coating stability, which affects how much can reasonably be stocked at once without waste.
Why Does Supplier Consolidation Matter for Cath Lab Procurement?
Cath lab procurement teams often weigh the benefits of consolidating purchases with fewer suppliers against maintaining multiple vendor relationships per device category. Fewer suppliers can simplify contracting, reduce administrative overhead, and sometimes improve pricing through volume commitments, but it can also concentrate supply risk if a single vendor experiences a shortage. Many labs land on a hybrid approach: a primary supplier covering the bulk of routine stent and balloon needs, with secondary relationships maintained for specialty devices or as a supply continuity safeguard. Regulatory documentation — CE marking, ISO 13485 quality certification, and clear IFUs — should be verified for every supplier considered, regardless of portfolio size.
What Role Do Manufacturer Relationships Play Beyond the Product Itself?
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Should a cath lab rely on a single device supplier or multiple suppliers?
Many labs use a hybrid model — a primary supplier for the bulk of routine coronary stent and balloon needs, with additional vendor relationships maintained for specialty devices or supply continuity. The right balance depends on the lab's size, case complexity, and risk tolerance around supply chain disruption.